← Leaderboards
Richard C. Mohs
Mount Sinai School Of Medicine Of Nyu
$30,035,943
Attributed
$30,035,943
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.8M · FY2017–22$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$34,083,801 · 6
By mechanism
R01$24,186,020 · 1
P01$5,256,690 · 3
R56$4,000,000 · 1
P50$641,091 · 1
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Ali G Gharavi$45,808,576
- Scott H Sicherer$26,739,771
- Lewis Silverman$10,485,930
- Dushyant P Purohit$2,792,474
- Kurt P. Schulz$3,189,700
Others in their field
Top investigators on “Alzheimer'S Disease”
- Paul S. Aisen · Cognition Therapeutics, Inc.$200,724,578
- Randall J Bateman · Washington University$184,115,182
- Michael W Weiner · Northern California Institute Res &Educ$175,732,070
- Reisa A. Sperling · Banner Health$139,117,861
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$124,251,847
- Sid E O'Bryant · University Of North Texas Hlth Sci Ctr$124,049,392
Research focus
Alzheimer'S DiseaseClinical ResearchEarly DiagnosisNeuropathologyGenotypeBiomedical FacilityAlzheimer&AposDementiaFundingDisease ProgressionClinical TrialsAmyloidDisease /Disorder OnsetData ManagementFamily GeneticsData Collection Methodology /EvaluationDoseBiomarker DevelopmentAmnestic Mild Cognitive ImpairmentBrain Disorder DiagnosisCaregiversCognition DisordersAttentionEpilepsy
Grant awards (30)
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$1,595,216
R01 · FY2022 · AG · contact PI
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$2,844,834
R01 · FY2021 · AG · contact PI
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,942,354
R01 · FY2020 · AG · contact PI
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,903,985
R01 · FY2020 · AG · contact PI
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,948,571
R01 · FY2019 · AG · contact PI
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,951,060
R01 · FY2018 · AG · contact PI
A Phase 3 pivotal trial of AGB101 to slow progression in MCI due to Alzheimer's Disease$4,000,000
R56 · FY2017 · AG · contact PI
Clinical/Biological Studies of Early Alzheimer's Disease$251,870
P01 · FY2002 · AG
CORE--INFORMATION TRANSFER$196,218
P50 · FY2002 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$0
P01 · FY2002 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$0
P01 · FY2002 · AG
CORE--DATA MANAGEMENT AND STATISTICS$0
P01 · FY2002 · AG
CORE--DATA MANAGEMENT AND STATISTICS$0
P01 · FY2002 · AG
CLIN AND BIOLOGIC STUDIES OF EARLY ALZHEIMERS DISEASE$1,733,524
P01 · FY2001 · AG
CORE--DATA MANAGEMENT AND STATISTICS$196,218
P01 · FY2001 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$196,218
P01 · FY2001 · AG
CORE--INFORMATION TRANSFER$196,218
P50 · FY2001 · AG
CLIN AND BIOLOGIC STUDIES OF EARLY ALZHEIMERS DISEASE$169,500
P01 · FY2001 · AG
CLIN AND BIOLOGIC STUDIES OF EARLY ALZHEIMERS DISEASE$74,173
P01 · FY2001 · AG
CORE--DATA MANAGEMENT AND STATISTICS$0
P01 · FY2001 · AG
CORE--DATA MANAGEMENT AND STATISTICS$0
P01 · FY2001 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$0
P01 · FY2001 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$0
P01 · FY2001 · AG
CLIN AND BIOLOGIC STUDIES OF EARLY ALZHEIMERS DISEASE$1,681,098
P01 · FY2000 · AG
CORE--INFORMATION TRANSFER$248,655
P50 · FY2000 · AG
CORE--DATA MANAGEMENT AND STATISTICS$211,980
P01 · FY2000 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$211,980
P01 · FY2000 · AG
CORE--DATA MANAGEMENT AND STATISTICS$196,218
P01 · FY2000 · AG
NEUROPSYCHOLOGY OF EARLY ALZHEIMERS DISEASE$196,218
P01 · FY2000 · AG
CLIN AND BIOLOGICAL STUDIES OF EARLY ALZHEIMER'S DISEASE$137,693
P01 · FY2000 · AG